These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

127 related items for PubMed ID: 11366883

  • 1. Antiretrovirals for HIV nephropathy?
    Saag M, Hecht F.
    AIDS Clin Care; 1999 Jun; 11(6):50. PubMed ID: 11366883
    [Abstract] [Full Text] [Related]

  • 2. Antiretroviral rounds. When success is a pain.
    Bartlett JG, del Rio C.
    AIDS Clin Care; 2001 Aug; 13(8):74-5. PubMed ID: 11547461
    [No Abstract] [Full Text] [Related]

  • 3. The efficacy of combined zidovudine and lamivudine compared with that of combined zidovudine, lamivudine and nelfinavir in asymptomatic and early symptomatic HIV-infected children.
    Moolasart P, Likanonsakul S.
    Southeast Asian J Trop Med Public Health; 2002 Jun; 33(2):280-7. PubMed ID: 12236426
    [Abstract] [Full Text] [Related]

  • 4. Immune restoration in HIV-positive, antiretroviral-naive patients after 1 year of zidovudine/lamivudine plus nelfinavir or nevirapine.
    Plana M, Ferrer E, Martínez C, Podzamczer D, García F, Maleno MJ, Barceló JJ, García A, Barberá MJ, Lacarcel M, Miró JM, Gallart T, Gatell JM.
    Antivir Ther; 2004 Apr; 9(2):197-204. PubMed ID: 15134181
    [Abstract] [Full Text] [Related]

  • 5. Update on antivirals.
    PI Perspect; 1996 Sep; (No 19):7-9. PubMed ID: 11363906
    [Abstract] [Full Text] [Related]

  • 6. Nelfinavir (Viracept).
    Baker R, Bowers M.
    BETA; 1997 Mar; ():5. PubMed ID: 11364528
    [Abstract] [Full Text] [Related]

  • 7. Too little of a good thing.
    Friedland GH, Gulick RM.
    AIDS Clin Care; 1998 Oct; 10(10):76-7. PubMed ID: 11365860
    [Abstract] [Full Text] [Related]

  • 8. A multicentre study to determine the efficacy and tolerability of a combination of nelfinavir (VIRACEPT), zalcitabine (HIVID) and zidovudine in the treatment of HIV infected Nigerian patients.
    Idoko JA, Akinsete L, Abalaka AD, Keshinro LB, Dutse L, Onyenekwe B, Lhekwaba A, Njoku OS, Kehinde MO, Wambebe CO.
    West Afr J Med; 2002 Oct; 21(2):83-6. PubMed ID: 12403023
    [Abstract] [Full Text] [Related]

  • 9. Alteration of complement protein levels after antiretroviral therapy in HIV-infected persons.
    Spear GT, Olinger G, Sullivan BL, Landay AL, Kessler H, Connick E, Kuritzkes D, St Clair M, Spritzler J, Wu H, Lederman MM.
    AIDS Res Hum Retroviruses; 1999 Dec 10; 15(18):1713-5. PubMed ID: 10606095
    [No Abstract] [Full Text] [Related]

  • 10. Predicting the duration of antiviral treatment needed to suppress plasma HIV-1 RNA.
    Rizzardi GP, De Boer RJ, Hoover S, Tambussi G, Chapuis A, Halkic N, Bart PA, Miller V, Staszewski S, Notermans DW, Perrin L, Fox CH, Lange JM, Lazzarin A, Pantaleo G.
    J Clin Invest; 2000 Mar 10; 105(6):777-82. PubMed ID: 10727446
    [Abstract] [Full Text] [Related]

  • 11. AVANTI 2. Randomized, double-blind trial to evaluate the efficacy and safety of zidovudine plus lamivudine versus zidovudine plus lamivudine plus indinavir in HIV-infected antiretroviral-naive patients.
    AIDS; 2000 Mar 10; 14(4):367-74. PubMed ID: 10770538
    [Abstract] [Full Text] [Related]

  • 12. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug 10; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 13. Switching to zidovudine plus lamivudine plus abacavir maintains viral suppression in patients with high viral load before antiretroviral therapy: a retrospective clinical cohort analysis.
    Moyle GJ, Gazzard BG.
    AIDS; 2002 May 03; 16(7):1086-7. PubMed ID: 11953482
    [No Abstract] [Full Text] [Related]

  • 14. Delavirdine combination and viral load.
    Anderson S.
    AIDS Treat News; 1997 Oct 17; (No 281):6. PubMed ID: 11364793
    [Abstract] [Full Text] [Related]

  • 15. Comparison of two once-daily regimens with a regimen consisting of nelfinavir, didanosine, and stavudine in antiretroviral therapy-naïve adults: 48-week results from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH, Wensing AM, Hassink EA, ten Kate RW, Richter C, Schreij G, Koopmans PP, Juttmann JR, van der Tweel I, Lange JM, Borleffs JC.
    HIV Clin Trials; 2005 Oct 17; 6(5):235-45. PubMed ID: 16306030
    [Abstract] [Full Text] [Related]

  • 16. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E, M98-863 Study Team.
    N Engl J Med; 2002 Jun 27; 346(26):2039-46. PubMed ID: 12087139
    [Abstract] [Full Text] [Related]

  • 17. Triple nucleoside combination zidovudine/lamivudine/abacavir versus zidovudine/lamivudine/nelfinavir as first-line therapy in HIV-1-infected adults: a randomized trial.
    Matheron S, Descamps D, Boué F, Livrozet JM, Lafeuillade A, Aquilina C, Troisvallets D, Goetschel A, Brun-Vezinet F, Mamet JP, Thiaux C, CNA3007 Study Group.
    Antivir Ther; 2003 Apr 27; 8(2):163-71. PubMed ID: 12741629
    [Abstract] [Full Text] [Related]

  • 18. Triple nuke therapy--results after one year.
    TreatmentUpdate; 2001 Apr 27; 12(10):3-4. PubMed ID: 11570063
    [No Abstract] [Full Text] [Related]

  • 19. Incidence and predictors of virologic failure of antiretroviral triple-drug therapy in a community-based cohort.
    Paris D, Ledergerber B, Weber R, Jost J, Flepp M, Opravil M, Ruef C, Zimmerli S.
    AIDS Res Hum Retroviruses; 1999 Dec 10; 15(18):1631-8. PubMed ID: 10606086
    [Abstract] [Full Text] [Related]

  • 20. AVANTI 3: a randomized, double-blind trial to compare the efficacy and safety of lamivudine plus zidovudine versus lamivudine plus zidovudine plus nelfinavir in HIV-1-infected antiretroviral-naive patients.
    Gartland M, AVANTI Study Group.
    Antivir Ther; 2001 Jun 10; 6(2):127-34. PubMed ID: 11491417
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.